STOCK TITAN

ClearPoint Neuro to Present at the 2021 Stifel Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ClearPoint Neuro, a leader in brain therapy navigation and delivery, announced its participation in the 2021 Stifel Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. ET. Interested parties can register by contacting Stifel. An online archive of the presentation will be available for 90 days on ClearPoint's website. The company focuses on improving patient quality of life through precise neurological therapies and collaborates with over 35 partners globally. Its navigation system is FDA-cleared and installed at over 60 sites, supporting over 4,500 clinical cases.

Positive
  • None.
Negative
  • None.

SOLANA BEACH, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the 2021 Stifel Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:40 a.m. Eastern Time via invite only. Registration is available by contacting StifelCorporateEvents@stifel.com.

An online archive of the broadcast will be available for 90 days on the Company’s website at www.clearpointneuro.com, on the “Investor Relations” page.

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with over 35 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and worldwide partners. For more information, please visit www.clearpointneuro.com.  

Forward-Looking Statements

Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2021, both of which have been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2021, which the Company intends to file with the Securities and Exchange Commission on or before November 15, 2021.


FAQ

What event is ClearPoint Neuro participating in on November 16, 2021?

ClearPoint Neuro will present at the 2021 Stifel Virtual Healthcare Conference on November 16, 2021, at 10:40 a.m. Eastern Time.

How can I access the ClearPoint Neuro presentation from the Stifel Conference?

The presentation will be archived online for 90 days on ClearPoint Neuro's website under the 'Investor Relations' page.

What is the ClearPoint Neuro Navigation System used for?

The ClearPoint Neuro Navigation System is used for deep brain stimulation, laser ablation, biopsy, and drug delivery to the brain.

How many clinical sites use the ClearPoint Neuro Navigation System?

The ClearPoint Neuro Navigation System is installed at over 60 active sites across the United States, Canada, and Europe.

How many cases has ClearPoint Neuro's system supported?

ClearPoint Neuro's system has supported over 4,500 clinical cases.

ClearPoint Neuro, Inc.

NASDAQ:CLPT

CLPT Rankings

CLPT Latest News

CLPT Stock Data

412.64M
25.42M
7.83%
30.52%
2.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
SOLANA BEACH